A tablet which is easy to ingest, contains 500 mg of levofloxacin, has a mass of 570 to 700 mg, a projected area of 90 to 125 mm2 on a plan view and a hardness of 30 to 300 N, and can be divided easily.

Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infe...

The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione...

Provided is a pravastatin sodium tablet rapidly disintegrating in the oral cavity, which shows rapid disintegration properties and a high solubility when put into the oral cavity or water, has such a hardness as causing no breakage in the course of production and distribution, has a high storage stability and has an equivalent bioavailability to a pravastatin sodium tablet that is to be taken together with water. The aforesaid pravastatin sodium tablet rapidly disintegrating in the oral cavity c...

Composition comprising olmesartan medoxomil (angiotensin II receptor antagonist), amlodipine, preferably, amlodipine besylate (calcium channel blocker) and hydrochlorothiazide (diuretic). Preferably the composition is a solid dosage form, in particular a tablet and has less than 7.3% concentration (w/w) of total impurities. The composition preferably has less than 2.5% concentration (w/w) of 4- (1-hydroxy-1-methylethyl)-2-propyl -1-[[2'-(1H-tetrazol-5-y1)biphenyl-4-y1]methyl]-1H-imidazol-5-carbo...

Disclosed is a pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. The pharmaceutical composition contains (A) olmesartan medoxomil, (B) amlodipine and (C) a calcium-containing additive.

Disclosed is a pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. The pharmaceutical composition contains (A) olmesartan medoxomil, (B) amlodipine and (C) a calcium-containing additive.

The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof.

The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof.